Unique in its approach, the Amyloidosis Center provides exceptional care for patients with all forms of systemic and localized amyloidosis through the support of laboratory and clinical research
Our laboratory and clinical research is supported by grants from the government and from foundations, and by individual donations. These are vital for support of our mission to help us in our quest for a cure for amyloidosis.
This one-hour on-demand video learning module features a panel of expert multidisciplinary providers who specialize in the treatment of ATTR (Transthyretin) Amyloidosis. Their discussion includes a didactic presentation supplemented by patient-case reviews and video vignette interviews of an actual patient living with amyloidosis. ATTR Activity Link
A New Chapter in the ATTR Story: From Nihilism to Optimism is a thought-provoking, on‑demand CME activity released on June 30, 2025, with the podcast launched on July 8, 2025. Ideal for clinicians in cardiology, neurology and multidisciplinary teams, the program delves into early diagnosis, therapeutic strategies, and best practices for managing ATTRv-CM and ATTRv-PN based on the latest clinical […]
Join us for the 4th annual FarmFest on Saturday, August 9th at Highland Homestead in Pawcatuck, CT! FarmFest 2025 is dedicating proceeds from this year’s music festival to the BU Chobanian & Avedisian School of Medicine Amyloidosis Center. Enjoy a day of community on the farm with all-day local music & vendors to support the […]
https://medicaldigest.org/scientific-contents/interview:unraveling-data-and-care-strategies-al-amyloidosis
Dr Sanchorawala discusses new research presented at the 66th Annual Meeting of American Society of Hematology in San Diego, CA in December 2024. https://www.vjhemonc.com/event/amyloidosis-sessions-highlights-from-ash-2024/
Few treatment options exist for patients with this life-threatening rare disease. New research is trying to change that.
The HELIOS B trial, recently published in NEJM, has unveiled promising results for patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran, a cutting-edge siRNA therapy, significantly reduced the risk of death and cardiac events compared to placebo. Over 36 months, Vutrisiran also showed improvements in walking distance and quality of life. These findings highlight a […]
Click here to view a synopsis of the BU Amyloidosis Center's attendance at the International Symposium on Amyloidosis at the Mayo Clinic May 26-30, 2024.